NEOVASC INC (NVCN) Stock Price, Forecast & Analysis
NASDAQ:NVCN • CA64065J4037
NVCN Key Statistics, Chart & Performance
The current stock price of NVCN is 30.03 USD. In the past month the price increased by 3.41%. In the past year, price increased by 212.49%.
NVCN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NVCN. When comparing the yearly performance of all stocks, NVCN is one of the better performing stocks in the market, outperforming 99.36% of all stocks.
NVCN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCN. NVCN may be in some trouble as it scores bad on both profitability and health.
NVCN Financial Highlights
Over the last trailing twelve months NVCN reported a non-GAAP Earnings per Share(EPS) of -105.01. The EPS decreased by -1143.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.81 |
NVCN Forecast & Estimates
NVCN Ownership
NVCN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.85 | 200.474B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.39 | 174.759B | ||
| SYK | STRYKER CORP | 25.25 | 147.128B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.45 | 110.292B | ||
| BDX | BECTON DICKINSON AND CO | 11.66 | 52.52B | ||
| IDXX | IDEXX LABORATORIES INC | 43.62 | 49.757B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.62 | 47.84B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.81 | 38.219B | ||
| RMD | RESMED INC | 20.58 | 37.992B | ||
| DXCM | DEXCOM INC | 28.98 | 28.573B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVCN
Company Profile
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.
Company Info
NEOVASC INC
Richmond, 5138-13562 Maycrest Way
Richmond British Columbia BRITISH COLUMBIA V6V 2J7 CA
CEO: Fred Colen
Employees: 71
Phone: 16042704344.0
NEOVASC INC / NVCN FAQ
What does NVCN do?
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures, and markets products for the cardiovascular marketplace. The firm is engaged in the development of minimally invasive therapies in cardiovascular care: refractory angina and mitral valve regurgitation. Its products include the Neovasc Reducer (Reducer), for the treatment of refractory angina, and the Tiara (Tiara), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. The firm operates through one business segment: the development, manufacturing and marketing of medical devices. The firm's subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc. The firm carries its business in Canada, the United States and Europe.
Can you provide the latest stock price for NEOVASC INC?
The current stock price of NVCN is 30.03 USD. The price increased by 1.66% in the last trading session.
Does NEOVASC INC pay dividends?
NVCN does not pay a dividend.
What is the ChartMill technical and fundamental rating of NVCN stock?
NVCN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of NEOVASC INC (NVCN)?
NEOVASC INC (NVCN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-105.01).
Can you provide the upcoming earnings date for NEOVASC INC?
NEOVASC INC (NVCN) will report earnings on 2023-05-10, after the market close.